Monday, Oct 7, 2002
South San Francisco, Calif. -- October 7, 2002 --Genentech, Inc. (NYSE: DNA) announced today two senior appointments in the company's Medical Affairs and Research organizations: Gwen Fyfe, M.D., is promoted to vice president, Clinical Hematology/Oncology, and Kenneth Hillan, MB ChB, FRCS, MRCPath, is promoted to vice president, Research Operations and Pathology.
Gwen Fyfe, vice president, Clinical Hematology/Oncology
Fyfe, 50, joined Genentech in 1997 as director of Oncology in Medical Affairs, and was named senior director in 1999. While at Genentech, Fyfe’s responsibilities have included managing the clinical trials that led to the approvals of Herceptin®, a humanized antibody approved for the treatment of HER2-positive metastatic breast cancer, and Rituxan®, the first therapeutic antibody for non-Hodgkin’s lymphoma approved in the United States. In her position as vice president, Clinical Hematology/Oncology, Fyfe is responsible for overseeing Genentech’s clinical trials in these two important areas of Genentech’s business.
"Gwen has been extremely effective in driving the clinical development of Genentech’s oncology pipeline," said Hal Barron, vice president of Medical Affairs. "Her broad experience and strong leadership will further strengthen Genentech’s clinical programs in hematology and oncology."
Fyfe holds bachelor and medical degrees from the Washington University Medical School in St. Louis. She performed residency training in pediatrics at the University of California, San Francisco and postdoctoral fellowship training in immunology at Washington University Medical School in St. Louis. During her career, Fyfe has published more than 20 articles in peer-reviewed journals.
Kenneth Hillan, vice president, Research Operations and Pathology
Hillan, 41, came to Genentech in 1994 to study the role of hepatocyte growth factor in liver regeneration. He joined the Pathology department as a scientist in 1996 and was promoted to director of Pathology in 1998. He was named senior director of Research Operations in 2001. In his role as vice president, Research Operations and Pathology, Hillan is responsible for operational management of Genentech’s Research organization, ensuring consistent implementation of strategic objectives and improvements in Research productivity. He also manages the Pathology department and its ongoing work in oncology, immunology, vascular biology and other therapeutic areas.
"This promotion recognizes Kenneth’s scientific expertise as well as his valuable contributions to shaping the strategic direction for Genentech’s Research organization," said Richard Scheller, Ph.D., senior vice president, Research.
Hillan graduated in medicine from Glasgow University in Scotland in 1983. He was named a Fellow of the Royal College of Surgeons (FRCS) in 1989 and was named a Member of the Royal College of Pathologists (MRCPath) in 1993. He also is an Honorary Professor of Molecular and Therapeutic Pathology at the University of Leeds. Hillan is on the editorial advisory board of the Journal of Pathology and is an ad hoc reviewer for the Journal of Clinical Pathology and the American Journal of Pathology and Liver. He has published more than 40 articles in peer-reviewed journals.
Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. Fifteen of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes ten biotechnology products directly in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA.
# # #